-
公开(公告)号:US20180305318A1
公开(公告)日:2018-10-25
申请号:US15771085
申请日:2016-10-28
申请人: BIOVENTURES, LLC , THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (WASHINGTON, DC)
发明人: Jawahar L. Mehta , Magomed Khaidakov , Kottayil I. Varughese , Shraddha Thakkar , Yao Dai , Peter Crooks , Narsimha Reddy Penthala
IPC分类号: C07D231/12
CPC分类号: C07D231/12 , C07D231/14 , C07D231/38 , C07D233/22 , C07D233/28
摘要: Inhibitors of oxidized low-density lipoprotein receptor 1 (LOX-1), compositions comprising inhibitors of LOX-1, and methods of using thereof are described.
-
公开(公告)号:US20200093831A1
公开(公告)日:2020-03-26
申请号:US16695653
申请日:2019-11-26
发明人: John Gerard Geisler , Robert Alonso , Peter Anthony Crooks , Narsimha Reddy Penthala , Zaineb Albayati
IPC分类号: A61K31/5375 , C07C229/22 , C07C229/08 , A61K31/4402 , A61K31/44 , C07C229/26 , C07C271/52 , C07C219/04 , C07C271/44 , A61K31/221 , C07F9/09 , A61K31/661 , A61K31/4406 , A61K31/223 , C07C205/37 , A61K31/27 , A61K31/265 , A61K31/40 , C07F9/12 , C07C323/58 , A61K31/4409 , A61K31/06 , A61K31/495 , A61K31/4453
摘要: A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.
-
公开(公告)号:US10239844B2
公开(公告)日:2019-03-26
申请号:US15909229
申请日:2018-03-01
申请人: BioVentures, LLC
IPC分类号: C07D249/06 , C07D401/04 , C07D409/04 , C07D405/04
摘要: The present invention relates to disubstituted triazoles, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I) are provided.
-
公开(公告)号:US10100029B2
公开(公告)日:2018-10-16
申请号:US15849150
申请日:2017-12-20
申请人: BioVentures, LLC
IPC分类号: C07D333/60 , C07D307/79 , C07D277/64 , C07D209/18 , C07D307/80 , C07D215/14
摘要: The present invention relates novel heterocyclic analogs of combretastatin, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I), Formula (II), and Formula (V) are provided.
-
公开(公告)号:US11465972B2
公开(公告)日:2022-10-11
申请号:US16721103
申请日:2019-12-19
申请人: United States Government as represented by the Department of Veterans Affairs , Bioventures, LLC
发明人: Jawahar L. Mehta , Magomed Khaidakov , Kottayil I. Varughese , Shraddha Thakkar , Yao Dai , Peter Crooks , Narsimha Reddy Penthala
IPC分类号: A61K31/4164 , A61K31/415 , C07D231/12 , C07D231/38 , C07D231/14 , C07D233/28 , C07D233/22
摘要: Inhibitors of oxidized low-density lipoprotein receptor 1 (LOX-1), compositions comprising inhibitors of LOX-1, and methods of using thereof are described.
-
公开(公告)号:US10548900B2
公开(公告)日:2020-02-04
申请号:US15451938
申请日:2017-03-07
发明人: John Gerard Geisler , Robert Alonso , Peter Anthony Crooks , Narsimha Reddy Penthala , Zaineb Albayati
IPC分类号: A61K31/535 , A61K31/5375 , A61K31/4453 , A61K31/495 , A61K31/06 , A61K31/221 , A61K31/223 , A61K31/265 , A61K31/27 , A61K31/40 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/661
摘要: A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.
-
公开(公告)号:US20230100940A1
公开(公告)日:2023-03-30
申请号:US17840436
申请日:2022-06-14
发明人: John Gerard Geisler , Robert Alonso , Peter Anthony Crooks , Narsimha Reddy Penthala , Zaineb Albayati
IPC分类号: A61K31/5375 , A61K31/4453 , A61K31/495 , A61K31/06 , A61K31/4409 , C07C323/58 , C07F9/12 , A61K31/40 , A61K31/265 , A61K31/27 , C07C205/37 , A61K31/223 , A61K31/4406 , A61K31/661 , C07F9/09 , A61K31/221 , C07C271/44 , C07C219/04 , C07C271/52 , C07C229/26 , A61K31/44 , A61K31/4402 , C07C229/08 , C07C229/22
摘要: A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.
-
公开(公告)号:US11406642B2
公开(公告)日:2022-08-09
申请号:US16695653
申请日:2019-11-26
发明人: John Gerard Geisler , Robert Alonso , Peter Anthony Crooks , Narsimha Reddy Penthala , Zaineb Albayati
IPC分类号: A61K31/5375 , A61K31/4453 , A61K31/495 , A61K31/06 , A61K31/4409 , C07C323/58 , C07F9/12 , A61K31/40 , A61K31/265 , A61K31/27 , C07C205/37 , A61K31/223 , A61K31/4406 , A61K31/661 , C07F9/09 , A61K31/221 , C07C271/44 , C07C219/04 , C07C271/52 , C07C229/26 , A61K31/44 , A61K31/4402 , C07C229/08 , C07C229/22 , C07D295/145 , C07D295/088 , C07D295/205 , C07D213/40 , C07D295/13
摘要: A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.
-
公开(公告)号:US20180186756A1
公开(公告)日:2018-07-05
申请号:US15909229
申请日:2018-03-01
申请人: BioVentures, LLC
IPC分类号: C07D249/06 , C07D401/04 , C07D405/04 , C07D409/04
CPC分类号: C07D249/06 , C07D401/04 , C07D405/04 , C07D409/04
摘要: The present invention relates to disubstituted triazoles, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I) are provided.
-
公开(公告)号:US20170362254A1
公开(公告)日:2017-12-21
申请号:US15532413
申请日:2015-12-03
申请人: BioVentures, LLC
发明人: Venumadhav Janganati , Peter Crooks , Narsimha Reddy Penthala , Craig Jordan , Shobanbabu Bommagani , Jessica Ponder
IPC分类号: C07D519/00 , C07F7/18
CPC分类号: C07D519/00 , C07F7/1804
摘要: The present disclosure provides dimers of melampomagnolide B (MMB), including carbamate, carbonate, succinic amide, ester and carboxamide dimers of MMB. These derivatives are useful for treating cancer in humans, in particular in treating leukemia, including acute myelogenous leukemia (AML). A compound comprising Formula (1) wherein: Z is independently selected from the group consisting of CH2, O, C(O), and CH, wherein when Z is CH, Z is connected to Y via a double bond and Y is N.
-
-
-
-
-
-
-
-
-